ALNYHealthcare · BiotechnologyThe 29 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. hold a median 12-month price target of $350 — +50.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 10 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Alnylam Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (14): The shares have been drifting down relative to others.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ALNY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +50.4% from it.
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $350 → $345 |
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | $375 → $369 |
| 30 Sept 2026 | JP Morgan | Maintains | Overweight | — |
| 21 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $455 |
| 8 Sept 2026 | Jefferies | Maintains | Hold | — |
| 8 Sept 2026 | Jefferies | Maintains | Hold | $230 → $260 |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $455 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $318 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 14 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 14 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $316 → $256 |
| 4 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $485 → $455 |
| 4 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Aug 2026 | Truist Securities | Maintains | Buy | $410 → $315 |
| 4 Aug 2026 | Truist Securities | Maintains | Buy | — |
| 3 Aug 2026 | Barclays | Maintains | Overweight | — |
| 3 Aug 2026 | Barclays | Maintains | Overweight | $527 → $450 |
| 3 Aug 2026 | Citigroup | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALNY appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Alnylam Pharmaceuticals, Inc. returned −49.1% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 20% of US stocks
Cheaper than 4% of US stocks
Cheaper than 9% of US stocks
Higher than 89% of US stocks
Higher than 79% of US stocks
Higher than 89% of US stocks
Higher than 76% of US stocks
Higher than 79% of US stocks
Higher than 96% of US stocks
Higher than 95% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alnylam Pharmaceuticals, Inc. has a market value of $31.1B and an enterprise value of $30.8B.
Revenue in the twelve months to 30 June 2026: $4.8B. The latest quarter grew 66.9% year on year.
Net income over the same four quarters: $808.0M, a 16.8% net margin.
Diluted earnings per share, trailing twelve months: $5.38.
Free cash flow in the twelve months to 30 June 2026: $819.9M.
Trailing P/E: 39.2×; forward P/E: 18.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alnylam Pharmaceuticals, Inc. employs 2,500 people — $1.9M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alnylam Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alnylam lowered its full-year revenue guidance after Amvuttra sales came in slower than expected. The comparison notes that Ionis had two pipeline setbacks on the same day in July.
Why it matters — ALNY watchers may weigh the reduced guidance and slower Amvuttra sales against the competitor setbacks discussed in the article.
CNBC’s “Closing Bell Overtime” featured Goldman Sachs lead U.S. biotech analyst Salveen Richter discussing biotech innovations in China and noting that large biopharma companies are looking at China assets.
Why it matters — The segment covers developments in the broader biotech sector, but the excerpt provides no specific information about Alnylam.
Law Offices of Howard G. Smith announced it is continuing its investigation into Alnylam Pharmaceuticals, Inc. regarding possible violations of federal securities laws, on behalf of investors who may have lost money. The investigation concerns potential securities-law violations by the company.
Why it matters — An ongoing securities-fraud investigation and the prospect of shareholder losses raise legal and reputational concerns for Alnylam investors.
The Law Offices of Frank R. Cruz announced that it continues its investigation into Alnylam Pharmaceuticals, Inc. regarding possible violations of federal securities laws, and urged shareholders who lost money to contact the firm.
Why it matters — An ongoing securities fraud investigation into the company signals potential legal and regulatory exposure that could affect investor confidence in ALNY.
Alnylam Pharmaceuticals announced the launch of the AMVUTTRA® (vutrisiran) 'Play by Play' initiative, a U.S. educational program featuring former professional athletes living with ATTR-CM and their care teams. The initiative uses personal stories and expert perspectives to help people recognize the symptoms of transthyretin-mediated amyloidosis cardiomyopathy earlier.
Why it matters — ALNY watchers would care because this educational campaign raises awareness of ATTR-CM and the company's AMVUTTRA® product, potentially supporting earlier diagnosis and broader recognition of the condition.
The 29 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. have a median 12-month price target of $350, with estimates ranging from $256 to $536. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering Alnylam Pharmaceuticals, Inc., 22 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alnylam Pharmaceuticals, Inc. 49 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Oct 2026, Alnylam Pharmaceuticals, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +50.4% from the last close, and Ticker Nerd's factor model ranks Alnylam Pharmaceuticals, Inc. 49 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alnylam Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $256 to $536 over the next 12 months.
Alnylam Pharmaceuticals, Inc. returned -49.1% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics.
The most recent item we track (The Motley Fool, 10 Oct 2026): "Alnylam vs. Ionis: Here's the Better Bad-News Buy". Alnylam lowered its full-year revenue guidance after Amvuttra sales came in slower than expected. The comparison notes that Ionis had two pipeline setbacks on the same day in July.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.
CEO Dr. Yvonne L. Greenstreet M.B.A., M.D. · 2,500 employees · United States · https://www.alnylam.com
